Results 321 to 330 of about 152,178 (350)

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2017
openaire   +1 more source

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Nature Reviews Clinical Oncology, 2021
Yoshiaki Nakamura, Florian Lordick, Yelena Y Janjigian   +2 more
exaly  

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

The Lancet Oncology, 2019
S. Loi, A. Giobbie-Hurder, A. Gombos, T. Bachelot, R. Hui, G. Curigliano, M. Campone, L. Biganzoli, H. Bonnefoi, G. Jerusalem, R. Bartsch, M. Rabaglio-Poretti, R. Kammler, R. Maibach, M. Smyth, A. Di Leo, M. Colleoni, G. Viale, M. Regan, F. André   +19 more
semanticscholar   +1 more source

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2018
openaire   +1 more source

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Lancet Oncology, The, 2020
Sandra M Swain, Martina Uttenreuther-Fischer, Young-Hyuck Im   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2013
openaire   +2 more sources

HER2-targeted therapies — a role beyond breast cancer

Nature Reviews Clinical Oncology, 2019
Yung-Jue Bang
exaly  

Trastuzumab

Reactions Weekly, 2012
openaire   +2 more sources

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Nature Reviews Clinical Oncology, 2009
Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi   +2 more
exaly  

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Lancet, The, 2017
David A Cameron, Evandro de Azambuja, Ian Smith   +2 more
exaly